Location: RPAH/Melanoma Institute Australia North Sydney
Trial status: Open
Treatment type: Radiotherapy
Stage: IA to IIC
Intent of treatment:Recurrence prevention

Title: RTN2: A Randomised Trial of Post-Operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck

Location: Melanoma Institute Australia, North Sydney
Trial status: Open
Treatment type: Oral systemic
Stage: IIIA, IIIB, IIIC
Intent of treatment: To compare the clinical efficacy of combination therapy (BRAF inhibitor and MEK inhibitor) to placebo in patients with stage III  BRAF V600E/K mutation-positive melanoma

Title: A study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib compared to two placebos (inactive drugs) in the treatment of BRAF V600 E/K mutation-positive melanoma after surgery.

Location: Melanoma Institute Australia North Sydney/Westmead/ RPAH
Trial status: Open
Treatment type: Biomarker
Stage: IIIb/IIIc/IV
Intent of treatment:

Title: Biomarker evaluation of short-term administration of chemotherapeutic, immunological or biologic agents in patients with unresectable stage IIIb, IIIc or IV melanoma amenable to pre and post treatment biopsy. 

Location: Melanoma Institute Australia North Sydney/ RPAH
Trial status: Open
Treatment type: Radiation Therapy
Stage: IV
Intent of treatment:

Title: Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – A randomized phase III trial.

Location: RPAH/ Melanoma Institute Australia North Sydney
Trial Status: Open
Treatment type: Chemotherapy
Stage: Advanced
Intent of treatment: Recurrence prevention

Title: A study of the molecular profile of melanoma chemosensitivity and resistance in patients undergoing intravenous limb infusion for metastatic melanoma. 

Location Melanoma Institute Australia North Sydney/ RPAH
Trial Status: Screening phase: Closed/Randomisation Phase: Open
Treatment type: Surgical
Stage: IIA to IIIC
Intent of treatment: Recurrence prevention

Title: Multicenter Selective Lymphadenectomy Trial II (MSLTII): A phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node. 

Location: Melanoma Institute Australia North Sydney/ RPAH
Trial Status: Open
Treatment type: Adjuvant
Stage: IIb, IIc, IIIa (N1a), IIIb (N1a, N2a)
Intent of treatment: Recurrence prevention

Title: A Pilot study of 75 patients to assess the feasibility, safety and toxicity of oral vitamin D over a period of two years. Patients will be randomized to receive either active treatment or placebo.